|
KMID : 0578320200430030222
|
|
Molecules and Cells
2020 Volume.43 No. 3 p.222 ~ p.227
|
|
|
Identification of the Antidepressant Vilazodone as an Inhibitor of Inositol Polyphosphate Multikinase by Structure-Based Drug Repositioning
|
|
Lee Bo-Ah
Park Seung-Ju
Lee Seul-Gi
Park Seung-Eun
Lee Eun-Hye
Song Ji-Joon
Byun Young-Joo
Kim Se-Yun
|
|
|
Abstract
|
|
|
|
Inositol polyphosphate multikinase (IPMK) is required for the biosynthesis of inositol phosphates (IPs) through the phosphorylation of multiple IP metabolites such as IP3 and IP4. The biological significance of IPMK’s catalytic actions to regulate cellular signaling events such as growth and metabolism has been studied extensively. However, pharmacological reagents that inhibit IPMK have not yet been identified. We employed a structure-based virtual screening of publicly available U.S. Food and Drug Administration-approved drugs and chemicals that identified the antidepressant, vilazodone, as an IPMK inhibitor. Docking simulations and pharmacophore analyses showed that vilazodone has a higher affinity for the ATP-binding catalytic region of IPMK than ATP and we validated that vilazodone inhibits IPMK’s IP kinase activities in vitro . The incubation of vilazodone with NIH3T3-L1 fibroblasts reduced cellular levels of IP5 and other highly phosphorylated IPs without influencing IP4 levels. We further found decreased Akt phosphorylation in vilazodone-treated HCT116 cancer cells. These data clearly indicate selective cellular actions of vilazodone against IPMK-dependent catalytic steps in IP metabolism and Akt activation. Collectively, our data demonstrate vilazodone as a method to inhibit cellular IPMK, providing a valuable pharmacological agent to study and target the biological and pathological processes governed by IPMK.
|
|
|
KEYWORD
|
|
|
drug repositioning, inositol phosphate, IPMK, vilazodone, virtual screening
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|